RAPID MICRO BIOSYSTEMS (RPID) presents a deeply negative liquidation recovery posture as of March 31, 2026. The MFFAIS-computed cash liquidation value is -$25.7M, liquid liquidation value is -$22.5M, and operating liquidation value is -$5.0M. All three metrics are negative, confirming that even under the most favorable asset recovery assumptions, equity holders receive nothing in a wind-down scenario. The company holds $13.8M in cash and cash equivalents plus $9.1M in short-term investments ($22.9M combined liquid assets at near-100% recovery), against a liability stack that includes the Trinity Capital term loan facility (LSA entered August 2025, up to $45.0M senior secured, maturing September 2030, secured by all tangible and intangible assets), two operating leases with combined remaining minimum payments of $4.7M through July 2029, and supplier purchase commitments of $1.8M (2026) and $1.6M (2027). The LSA creates a senior secured creditor with a blanket lien on all assets including IP, which would subordinate any residual equity recovery in a liquidation. Interest expense jumped from less than $0.1M in Q1 2025 to $0.6M in Q1 2026 (a 5,225% increase), confirming the LSA drawdown has materially shifted the liability stack since the prior annual filing. Operating cash burn for Q1 2026 was -$15.1M, up from -$9.1M in Q1 2025, a 66% deterioration QoQ. At this burn rate, the $22.9M liquid pool covers less than two quarters without additional tranches or financing. The company acknowledges in its going-concern language that continued access to additional LSA tranches is subject to commercial/operational milestones with no guarantee of access. The accumulated deficit stands at $536.7M as of March 31, 2026. PP&E and inventory are present on the balance sheet but their specific values are not separately disclosed in the filing body provided; the prior annual filing (10-K for FY2025) indicates ROU assets of $3.98M (operating) and minimal financing lease assets, which would carry minimal liquidation value. All intangible assets and IP are pledged under the LSA lien and carry zero liquidation value under the lens. The TAG_CONTEXT provided is empty—no XBRL tags were supplied for this filing—so all balance sheet figures referenced here are sourced from the MD&A and footnote disclosures in the filing narrative. The filing does not separately tag balance sheet line items in the XBRL context provided, which limits tag-level analysis. No material change in operating lease commitments since the prior annual filing; the Lowell and Lexington leases were disclosed in the 10-K. The MilliporeSigma distribution agreement and Lonza integration are disclosed in narrative but have no determinable liquidation asset value.
▼ Community Notes